|
|
Post by bradmel on Aug 21, 2018 20:13:11 GMT -5
There has been a lot of news in the last week of a EpiPen shortage which have the HHS Secretary on a few of the TV news shows talking about this critical shortage. Secretary Alex Azar said that the FDA is allowing expired epipens to be utilized by patients up to 4 months past the expiration date of the medicine. He also is having open dialogue with other countries who have similar epinephrine devices to the EpiPen to contact HHS to see if we can import these medicines to the United States. www.youtube.com/watch?v=uXhNH6ZjNHc |
|
|
|
Post by peppy on Aug 21, 2018 20:18:17 GMT -5
There has been a lot of news in the last week of a EpiPen shortage which have the HHS Secretary on a few of the TV news shows talking about this critical shortage. Secretary ,,,,,,,said that the FDA is allowing expired epipens to be utilized by patients up to 4 months past the expiration date of the medicine. He also is having open dialogue with other countries who have similar epinephrine devices to the EpiPen to contact HHS to see if we can import thesde medicines to the United States. MNKD is looking or a licenser of our EPI. I could try to find the slide. Not sure why there is commentary on the bottom.  |
|
|
|
Post by brotherm1 on Aug 21, 2018 20:29:27 GMT -5
There has been a lot of news in the last week of a EpiPen shortage which have the HHS Secretary on a few of the TV news shows talking about this critical shortage. Secretary ,,,,,,,said that the FDA is allowing expired epipens to be utilized by patients up to 4 months past the expiration date of the medicine. He also is having open dialogue with other countries who have similar epinephrine devices to the EpiPen to contact HHS to see if we can import thesde medicines to the United States. MNKD is looking or a licenser of our EPI. I could try to find the slide. Not sure why there is commentary on the bottom. Peppy, where and when did the words below the chart talking about a possible press release in 2-3 weeks come from? |
|
|
|
Post by bradmel on Aug 21, 2018 20:29:54 GMT -5
Thanks Peppy!
I wish we were further along with this!
Timing is everything!
|
|
|
|
Post by peppy on Aug 21, 2018 20:46:30 GMT -5
I am clueless. brotherm1 2/20/2018 the date on the screencast. it looks like may have taken the slide from an article about MNKD. |
|
|
|
Post by madog365 on Aug 22, 2018 8:05:50 GMT -5
My belief is that the advancement of Mannkind's epihale was being pushed by former CMO who came from Mylan the Epi Pen maker. With his departure and the hire of David Kendall, it was pretty clear that Mannkind was going "all in" on the diabetes space.
I would think EpiHale is available for license with no further trials or research being done without a partner (aka no money spent on development)
I do believe they will advance Trep T but that will also have to be with a partner.
|
|
|
|
Post by mnkdfann on Aug 22, 2018 8:16:45 GMT -5
I am clueless. brotherm1 2/20/2018 the date on the screencast. it looks like may have taken the slide from an article about MNKD. It looks to me like it is excerpted from one of Spencer's articles. The phrasing sounds like his. And, IIRC, he has spoken about trading MNKD in light of binary events. |
|
|
|
Post by agedhippie on Aug 22, 2018 8:46:31 GMT -5
My belief is that the advancement of Mannkind's epihale was being pushed by former CMO who came from Mylan the Epi Pen maker. With his departure and the hire of David Kendall, it was pretty clear that Mannkind was going "all in" on the diabetes space. I would think EpiHale is available for license with no further trials or research being done without a partner (aka no money spent on development) I do believe they will advance Trep T but that will also have to be with a partner. I think that there are two streams; actively developed products, and brainstorming ideas. The brainstorming ideas are options where they think Technosphere could be used to deliver a drug and where they will do a minimal amount of work. These are effectively a shop window for Technosphere to pull in partners for these and other drugs. |
|
|
|
Post by mnholdem on Aug 22, 2018 8:47:39 GMT -5
MannKind is allocating its limited resources but is open to development partners for several of its Technosphere API.
|
|
|
|
Post by agusta on Aug 22, 2018 9:45:24 GMT -5
Last week was on National News that TEVA came out with a generic for Epi Pens (cheaper)....just did not see any comments as to how this fits into the EpiHale.
|
|
|
|
Post by traderdennis on Aug 22, 2018 11:28:19 GMT -5
Last week was on National News that TEVA came out with a generic for Epi Pens (cheaper)....just did not see any comments as to how this fits into the EpiHale. it makes it go from a marginal idea to a bad. It was margina when there was a severe shortage of epi pens and a very high price point. Now when Teva kicks in production the supply will be normalized and a downward pricing pressure. |
|
|
|
Post by boca1girl on Aug 22, 2018 12:27:27 GMT -5
Last week was on National News that TEVA came out with a generic for Epi Pens (cheaper)....just did not see any comments as to how this fits into the EpiHale. it makes it go from a marginal idea to a bad. It was margina when there was a severe shortage of epi pens and a very high price point. Now when Teva kicks in production the supply will be normalized and a downward pricing pressure. I agree that having cheaper generics available make EpiHale less attractive but would still be an alternative to jabbing yourself or another with a needle. I’ve read many comments that people would wait way too long to take the injection so maybe an inhalable alternative would still have good appeal. At this point, I doubt MNKD will spend any time on EpiHale without a partner funding it. |
|
